DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio

Friday, 4 November 2016


Dhileep Krishnamurthy

Dhileep Krishnamurthy

Vice President & Head Global R&D API



Piramal Enterprises Limited

Piramal Enterprises Limited


Pharmaceutical API Process R&D (NCE and Generics) Executive with broad international experience

Specialties:- API R&D Strategy development and implementation
- People and Scientific leadership (multicultural and multinational)
- Discovery and Development of competitively advantaged routes for NCE, Generics and LCM APIs
- Implementation of R&D turnarounds
- Demonstrated cost savings over 5 million US$ for many NCE and Generics API using R&D initiatives

Over 20 years of scientific and R&D leadership experience in academic, multinational big pharma, CRO, CMO and generic pharmaceutical companies in synthetic organic chemistry, API process R&D and providing CMC support for filing IND, NDA, and DMF. Key experience in R&D strengthening using total synthesis, competitively advantaged route scouting, asymmetric catalysis, chemo catalysis, technology transfer of APIs, and building customer vendor relationship. Demonstrated leadership experience in managing QbD by DoE, bio-catalysis, analytical R&D, PAT, high throughput polymorph and catalysis screening using automation, and crystal engineering.

Motivational leadership style with a record of building highly motivated technical teams for innovation and productivity.


Vice President & Global Head - API R&D

Piramal Enterprises
 – Present (3 years 10 months)Mumbai Area, India
Leading the R&D organization (4 in India, 1 UK and 1 Canadian site) in API business (CRAMS and Generics)
• Providing guidance to global API R&D as a strategic partner for competitive advantage for API business
• Facilitating the development of break-through in new and competitively advantaged routes using modern synthesis/analytics and supporting technologies like bio-catalysis and chemo-catalysis

Developed R&D Vision and Strategy
• Crafted the long term vision for the R&D in API business and implementing along-with the business head and other stakeholders
• Developed and implemented the R&D strategy for growth as per the crafted vision

Providing technical support to BD, SM and Supply Chain and Regulatory
• Supporting BD and SM in Sales by attending the BD and SM discussions with client
• Provide technical inputs to proposal development especially for high value deals

People-development and recruitment
• Created a motivated and engaged team
• Coaching the R&D leads in each API sites, while working alongside the site heads
• Guiding the capability development in API R&D teams
(Open)1 honor or award

Vice President and Head (API, Route Scouting and New Technologies)

SAI Life Sciences Ltd
 –  (1 year 1 month)Hyderabad Area, India
Led the R&D organization in route scouting and technologies in API business (CRAMS and Generics)

Vice president & Head of Chemistry

Dr. Reddy's Laboratories
 –  (9 months)Hyderabad
• Provided scientific leadership support to management council of Dr. Reddy's from product selection to execution of projects in a timely and cost effective manner.
• Provided scientific leadership support to development of economical, novel and robust API processes for global generics and API markets.
• Provided leadership support to a team that is responsible for identifying and developing the novel polymorphic form for API.
• Provided technical leadership support to tech transfer and validation batches and ensure successful execution of commercial batches at manufacturing facility.
• Executed cost and quality improvement solutions to commercial API processes.
• Provided leadership support for managing and mentoring about 100 scientists working together to deliver several DMFs per year. Successfully solved many scientific challenges with other cross functional teams consist of scientists and project managers in formulations, analytical, regulatory, QA, QC, IPM and Engineering in a matrix environment.
• Demonstrated proof of concept has been demonstrated for obtaining Japan quality material with no extra cost by application of fundamental understanding of science and technology.
• Demonstrated proof of concept has been demonstrated for synthesis of many complex APIs using economical, green and novel route.
• Guided the team to identify and develop several novel polymorphs for many APIs.

Associate Research Fellow

Sunovion Pharmaceuticals Inc.
 –  (3 years)Greater Boston Area, USA

Research Investigator

Bristol-Myers Squibb
 –  (2 years)NJ, USA

Honors & Awards

Fellow of Royal Society of Chemistry

Royal Society of Chemistry- UK

Achieving Fellow status in the chemical profession denotes to the wider community a high level of accomplishment as a professional chemist.

Gold Medal

Indian Chemical Society

Topper at Aptitude test in Chemistry with in Greater Bombay

American Institute of Chemist Award

American Institute of Chemist

Outstanding Ph.D Dissertation of the year

Henry Eyring Research Fellowship

Department of Chemistry, university of Utah


university of Utah, Salt Lake City, Utah (USA)

Doctor of Philosophy (Ph.D.), Synthetic Organic Chemistry

(Open)2 honors and awards

University of Mumbai

Bachelor's Degree, Chemistry

Vice President – Chemistry, Dr. Reddy’s Laboratories, INDIA

Dr. Dhileep Krishnamurthy
Dhileep holds a Ph.D. in Organic Chemistry from the University of Utah, US in 1995 and a Master's degree from Indian Institute of Technology Bombay. His Ph.D degree was focused on total synthesis of anti-tumor antibiotic natural product rhizoxin D and

the break through discovery of BITIP catalyzed asymmetric carbon-carbon bond forming reactions.
After a short Post-doctoral stint with Professor Gary Keck, he joined the process research group in Bristol-Myers Squib (BMS). At BMS he was instrumental in discovering the commercial route for anti-viral NCE "Entecavir". In 1999, he moved to Sepracor Inc., where his group contributed to number of fast track Improved Chemical Entities (ICE) projects. In late 2002, he joined Boehringer-Ingelheim (BI), where he was most recently served as Director for Process Research at R&D head quarter in USA. At BI, he held Management and Scientific responsibility of Process Chemistry group, Chemical Catalysis/Automation, Radio Synthesis group and API Crystallization group. His R&D responsibilities include design and synthesis of NCE based cGMP API's from multi gram to > 100 Kg for pre-clinical, clinical and formulation development. His research interest includes Discovery and Development of patent free, economical, green synthesis of API using traditional and modern approaches.
He has more than 60 Publications, Patents and Book Chapters. He has delivered many invited lectures in academic institutions and international professional conferences. Most recently, he served in the judging panel for the US Presidential Green Chemistry challenge award.
At present, Dr. Dhileep Krishnamurthy holds Vice President – Chemistry position and he is heading the chemistry function at IPDO, Dr. Reddy’s Laboratories, Hyderabad.

Dr. Dhileep Krishnamurthy's Abstract for IGCW 2011

Efficient Synthesis of Empagliflozin, an Inhibitor of SGLT-2, Utilizing an AlCl3-Promoted Silane Reduction of a β-Glycopyranoside

Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States
Org. Lett.201416 (16), pp 4090–4093
DOI: 10.1021/ol501755h
Publication Date (Web): July 25, 2014
Copyright © 2014 American Chemical Society


Abstract Image
An efficient production synthesis of the SGLT-2 inhibitor Empagliflozin (5) from acid 1 is described. The key tactical stage involves I/Mg exchange of aryl iodide 2 followed by addition to glucono lactone 3 in THF. Subsequent in situ treatment of the resulting lactol with HCl in MeOH produces β-anomeric methyl glycopyranoside 4 which is, without isolation, directly reduced with Et3SiH mediated by AlCl3 as a Lewis acid in CH2Cl2/MeCN to afford 5 in 50% overall yield. The process was implemented for production on a metric ton scale for commercial launch.

, and 
Org. Process Res. Dev.201115 (5), pp 1185–1191
Publication Date (Web): August 3, 2011 (Article)
DOI: 10.1021/op200175t
The synthesis of LFA-1 inhibitor BIRT2584 on metric-ton scale was accomplished by means of a safe and robust process. Highlights of the process include the asymmetric synthesis of the key advanced intermediate by implementation of Seebach’s self-...

, and 
Org. Lett.201416 (16), pp 4142–4145
Publication Date (Web): August 1, 2014 (Letter)
DOI: 10.1021/ol501833g
An efficient enantioselective synthesis of the chiral polycyclic cholesteryl ester transfer protein (CETP) inhibitor 1 has been developed. The synthesis was rendered practical for large scale via the development of a modified Hantzsch-type reaction to ...

Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877
Org. Lett.201012 (1), pp 176–179
DOI: 10.1021/ol9025815
Publication Date (Web): December 1, 2009
Copyright © 2009 American Chemical Society


Abstract Image
A series of novel, efficient, air-stable, and tunable chiral bisdihydrobenzooxaphosphole ligands (BIBOPs) were developed for rhodium-catalyzed hydrogenations of various functionalized olefins such as α-arylenamides, α-(acylamino)acrylic acid derivatives, β-(acylamino)acrylates, and dimethyl itaconate with excellent enantioselectivities (up to 99% ee) and reactivities (up to 2000 TON).